-
Product Insights
Hepatitis C – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis C - Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-0739 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-0739 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ASP-0739 in Solid Tumor Drug Details:ASP-0739 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ezurpimtrostat in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ezurpimtrostat in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Ezurpimtrostat (GNS-561) is under development for the...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bile Duct Cancer Pipeline Drugs Market Report Overview Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hepatitis C occurs with multiple symptoms including abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The Hepatitis C pipeline drugs market research report provides an analysis of the Hepatitis C drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Transforming Growth Factor Beta 1 (TGFB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The transforming growth factor beta 1 (TGFB1) targeted pipeline therapeutics report provides comprehensive information on TGFB1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in transforming growth factor beta 1 targeted therapeutics development with...
-
Product Insights
Transforming Growth Factor Beta 1 (TGFB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of...